Artivion, Inc. insider trading
Every open-market purchase and sale by Artivion, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Artivion, Inc.’s insiders pay?
From March 3, 2010 to September 11, 2026, 28 insiders reported 10 open-market purchases and 215 sales not made under a pre-set plan in Artivion, Inc. Twelve months after each purchase was reported, the shares were −3.8% against the S&P 500 on average (median −1.0%), over 7 purchases with a full year of prices; 29% beat the index. After sales, the shares moved +2.9% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 7, 2016 into $14,822 by November 2, 2026, +3.8% a year. It held shares 38% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $20,545 (+7.0% a year), and held throughout $44,845 (+15.2%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Holloway Jean F | SVP, General Counsel | 0 | — | — | 29 | −1.2% (22) | August 12, 2026 |
| Horton Amy | VP, Chief Accounting Officer | 0 | — | — | 25 | +10.8% (18) | March 4, 2026 |
| Davis John E | Chief Commercial Officer | 2 | −9.3% (2) | 0% | 16 | +5.8% (10) | March 4, 2026 |
| Mackin James P | President & CEO | 2 | −8.2% (2) | 50% | 16 | −2.8% (10) | August 20, 2026 |
| Ronald C Elkins | Director | 0 | — | — | 18 | +5.0% (16) | September 6, 2018 |
| Mccall Ronald D | Director | 0 | — | — | 17 | −12.3% (15) | August 26, 2021 |
| Stanton Marshall S. | SVP, Clinical & MD Affair | 0 | — | — | 16 | +2.4% (9) | March 4, 2026 |
| Lee David Ashley | Executive VP, COO & CFO | 2 | — | — | 8 | +6.3% (8) | March 3, 2023 |
| Anderson Bruce G. | VP, US Sales &Global Marketing | 0 | — | — | 9 | +3.7% (9) | December 10, 2014 |
| Capps Scott B | VP, Clinical Research | 0 | — | — | 7 | −17.4% (7) | December 16, 2020 |
| Getz Matthew A | VP, Human Resources | 0 | — | — | 7 | +19.2% (7) | August 19, 2024 |
| Green Andrew M | SVP, Regulatory and Quality | 0 | — | — | 7 | +13.1% (4) | September 11, 2026 |
| Maier Dennis B | SVP, Operations | 0 | — | — | 7 | −9.8% (7) | June 8, 2023 |
| Berry Lance A | EVP, COO, CFO & Treasurer | 0 | — | — | 6 | +33.1% (2) | August 17, 2026 |
| Anderson Steven G | Executive Chairman | 0 | — | — | 5 | +3.0% (4) | February 20, 2015 |
| Benson James | Director | 0 | — | — | 5 | +36.3% (5) | May 12, 2016 |
| Maney Rochelle L. | VP, Quality | 0 | — | — | 5 | +4.3% (5) | March 7, 2024 |
| Semedo Anthony B. | Director | 2 | +4.7% (2) | 50% | 2 | −0.2% (2) | May 27, 2025 |
| Fronk David | VP Reg. Affrs. and Qual Assur. | 0 | — | — | 3 | −17.8% (3) | May 19, 2014 |
| Ackerman Thomas F | Director | 0 | — | — | 1 | −8.8% (1) | May 5, 2011 |
| Bevevino Daniel J | Director | 0 | — | — | 1 | −8.4% (1) | May 6, 2011 |
| Bullock James | Director | 1 | −1.0% (1) | 0% | 0 | — | September 17, 2020 |
| Gale David C | VP, Research & Development | 0 | — | — | 1 | +43.7% (1) | November 17, 2017 |
| Hoff Elizabeth A | Director | 0 | — | — | 1 | — | November 19, 2025 |
| Morgan Harvey | Director | 0 | — | — | 1 | −22.8% (1) | August 15, 2018 |
| Salveson Jon W | Director | 1 | — | — | 0 | — | June 11, 2012 |
| Seery Gerald B | Sr. VP, Sales and Marketing | 0 | — | — | 1 | +51.5% (1) | December 3, 2012 |
| Tyrs Florian | VP, Global Operations | 0 | — | — | 1 | +14.9% (1) | February 28, 2024 |
When several insiders traded Artivion, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Artivion, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged +8.5% against the index. After 16 selling crowds, +9.0%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| August 31, 2026 | 4 selling | not yet | not yet | not yet |
| February 28, 2025 | 6 selling | +16.9% | +63.7% | +36.1% |
| August 30, 2024 | 3 selling | +1.5% | −10.6% | +45.6% |
| February 29, 2024 | 9 selling | +20.4% | +28.6% | +15.0% |
| March 31, 2023 | 10 selling | +22.8% | +11.0% | +35.0% |
| December 31, 2021 | 2 buying | +10.8% | +14.3% | −23.6% |
| September 30, 2021 | 3 selling | −19.7% | −10.0% | −22.4% |
| December 31, 2020 | 3 selling | −14.1% | +2.5% | −42.5% |
| September 30, 2020 | 2 buying | +13.5% | +2.7% | −9.3% |
| December 31, 2019 | 3 selling | −16.6% | −27.2% | −32.5% |
| May 31, 2019 | 5 selling | −13.7% | −30.1% | −33.5% |
| May 31, 2018 | 4 selling | +16.1% | +8.4% | +1.0% |